This is the second and final phase of the overall capacity addition of ?195 kL which was under construction at Unit IV Bidar facility
The CR Bio unit represents a non-core legacy asset with limited strategic alignment to our core CDMO operations
The company will provide the necessary response to USFDA within stipulated 15 days
Pivotal phase III SUNMO study demonstrated an 11.5 month median progression-free survival - three times longer than R-GemOx
The GMP-compliant facility with automated environmental monitoring accommodates both white room and class 7 and 8 cleanroom space
UFlex is the first and only Indian company to receive USFDA approval for its technology and capacity to recycle all three materials
Sun Pharma gets 8 observations from USFDA for Halol facility
The company received one observation in the Form-483
The inspection concluded successfully, with the facility found to be in compliance with the required regulations
Now approved for both acute and chronic HCV in adults and children aged 3 and above
Subscribe To Our Newsletter & Stay Updated
